Skip to main content

Table 1 Patients' demographic and baseline disease characteristics

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of patients (%)

Patients' characteristics

DD/DI arm (N = 86)

HDI arm (N = 80)

Age, years

    

Mean (SD)

47 (13)

 

52 (13)

 

Gender

    

Male

47

(55)

54

(67)

Female

39

(45)

26

(33)

ECOG Performance Status

    

0

81

(94)

76

(95)

1

5

(6)

4

(5)

Site of primary tumor

    

Head/neck

3

(3)

6

(7)

Trunk

50

(58)

40

(50)

Upper limb

7

(8)

6

(8)

Lower limb

26

(30)

24

(30)

Unknown

0

(0)

4

(5)

Ulceration

    

No

45

(52)

36

(45)

Yes

33

(39)

34

(43)

Unknown

8

(9)

10

(12)

Breslow's thickness (mm)

    

1

2

(2)

7

(9)

1.01 – 2.0

27

(31)

18

(23)

2.01 – 4.0

30

(35)

29

(36)

>4

22

(26)

17

(21)

Unknown

5

(6)

9

(11)

Nodal classification

    

N0

0

(0)

2

(2)

N1

56

(65)

46

(58)

N2

19

(22)

24

(30)

N3

11

(13)

8

(10)